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INTRODUCTION 
Chronic inflammation usually originates from a dysfunction in tolerance processes implicating a 
variety of soluble factors and immune cells. In homeostatic conditions, an inflammatory event 
triggering by, for instance, pathogen invasion, necrotic damaged cells or irritants is a natural 
process initiatedto protect the target tissue, remove the injurious stimulus,and then initiate the 
healing process. Such a process detects and engages immune cells that are able to restore 
toleranceconsequently. A defect in that process could lead to a continuous stimulation of immune 
cells, overpassing tolerogenic mechanisms andthus leading to chronic inflammation. Such a 
defect can implicate one or many factors and/or effector cells that can sustain inflammatory 
signals overwhelming inflammation. A way to break the inflammatory process is to reintroduce 
in the damaging loop factors that will favor the production of anti-inflammatory elements and 
desensitize immune responsesorchestrated byantigen presenting cells, thusallowing immune cells 
to take control all over again. One strategy is to use apoptotic cell injection in order to benefit 
from their direct and indirect immunomodulatory properties to favor tolerance induction. This 
has been already evaluated in many experimental models and proposedin a fewclinical trials.  
APOPTOTIC CELLS 
One of the key elements allowing restoration of homeostasis is apoptotic cell death. First, after 
doing their job such as elimination of pathogens, reactive T cells need to graciously disappear 
mainly through apoptotic cell death. Apoptotic cell death, i.e., apoptosis, is a physiological 
mechanism that allows the elimination of cells inexcess or unwantedcells preventing an 
inflammatory process (1, 2). The lack of inflammation associated with apoptosis is attributed to 
the fact that professional phagocytes (mainly macrophages and subpopulations of dendritic 
cells)–but also neighbor cells− efficiently engulf apoptotic cells and apoptotic residues called 
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apoptotic bodies. This prevents the secondary necrosis of apoptotic cells, a pro-inflammatory cell 
death (3),and so, the release of proteases and other inflammatory mediators as alarmines(4, 5)by 
late apoptotic/necrotic cells (3, 6, 7). Efficient apoptotic cell removal is governed by multiple 
signals delivered by apoptotic cells including: “find me” signals responsible for professional 
phagocyte attraction, the expression of “eat me” signals and the repression of “don’t eat me” 
signals to avoid the elimination of viable cells (Fig. 1)(8, 9). Regulation is also provided by 
“keep out” signals such as lactoferrinthat prevent neutrophil migration(10). 
 
The mechanisms associated with the efficient elimination of cells entering apoptosis are also 
associated with thoseallowing the preventionof the immune response initiation. These 
mechanisms are critical and redundant as they should prevent the occurrence of autoimmune 
diseases (11, 12). It is possible to distinguish two types of mechanisms: those directly related to 
apoptotic cell death and the others dependent on their elimination by phagocytic cells. Thus, 
phagocytes will shape a new microenvironment through the secretion of soluble factors affecting 
themselves as well as all the neighboring cells,preventing in concert the appearance of unwanted 
immune response deleterious to the host.  
DIRECT EFFECT OF APOPTOTIC CELLS 
Several studies report that during the process of apoptosis,apoptotic cells secrete 
immunosuppressive cytokines such as IL-10 and TGF-β (13, 14). TGF-β, stored in a latent form 
in intracellular compartments, is released during apoptosis (13). Cytokine release allows to 
generate immunosuppressive microenvironment, inhibits the secretion of pro-inflammatory 
cytokines (TNF-α or IL-1β) by macrophages (15, 16)and neutralize the development of an 
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effective immune response. This also prevents the initiation of an immune response targeting 
antigenspresent on –or expressed by− apoptotic cells, and thus prevents autoimmune responses. 
Indeed, apoptotic bodies escaping from removal have been reported to cluster clinical relevant 
auto-antigens at their surface(17). These auto-antigens are exposed at cell surface or translocated 
from internal compartments to cell membrane during early stages of apoptosis(18, 19). Apoptotic 
cells arealso able to clear or neutralize inflammatory chemokines, such as CCL3 and CCL5 via 
CCR5 expression, thus preventing the migration of other leukocytes (20). All these 
immunosuppressive effects are time-limited until the cell dislocation occurs through secondary 
necrosis and so, other mechanisms need to take place to prevent chronic inflammation. 
INDIRECT EFFECT OF APOPTOTIC CELLS  
Apoptotic cells also allow the development of an immunomodulatory environment indirectly 
through phagocytic cells. Indeed, professional phagocytic cells such as macrophages can release 
or express immunosuppressive molecules (IL-10, TGF-β, prostaglandin E2 or PGE-2, Fas 
ligand) in the clearance of apoptotic cells (21-23). Thus, apoptotic cells have immunosuppressive 
properties in vitro notably through the secretion of IL-10 which inducesin vivo immune deviation 
to type 2cytokine secretion (14, 21, 22). The production of TGF-β1 is observed during 
phagocytosis by macrophages or immature dendritic cells(15, 23). In addition, it has been shown 
that phagocytosis of apoptotic cells induce a down-regulation of IL-12 secretion as well as TNF 
by macrophages and could also block the synthesis of pro-inflammatory cytokines by interfering 
with NF-kappaB(24-26). The elimination of apoptotic neutrophils inhibits the synthesis of 
cytokines called "Th17", such as IL-23 and IL-17 by phagocytic cells (27). Altogether, this 
suggests that pro-inflammatory Th1 and Th17 responses are prevented by professional 
phagocytes participating in apoptotic cell removal. 
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ROLE OF MACROPHAGES AND DENDRITIC CELLS 
Macrophages appear to be the main phagocytic cells which remove most effectively apoptotic 
cells (15, 28, 29). Indeed, they express a large number of membrane receptors involved in this 
elimination (Fig.1). The stimulation of these receptors favors induction of 
animmunomodulatoryphenotype of the phagocytes. Many immunomodulatory mechanisms have 
been reported. They are represented mainly by the release of soluble factors such as cytokines 
IL-10 or TGF-β. Macrophage functions will be limited after removal of apoptotic cells. In 
addition, some subpopulations of dendritic cells have been involved also in the capture of 
apoptotic cells (23, 30-34). One study conducted on rats showed that a subpopulation of 
circulating dendritic cells would be responsible for capturing continuously apoptotic cells and 
bodies from intestinal epithelial cells removed every day after desquamation. Then, dendritic 
cells migrate to the mesenteric lymph nodeswhere they inactivate the naïve autoreactiveT 
cells(30, 32,35). Other experimental studies also suggest that the capture of apoptotic cells by 
dendritic cell subsets leads to tolerance (23, 31, 33, 34). In addition, an in vitro study 
showeddendritic cells that have captured apoptotic cells did not respond to lipopolysaccharide 
(36).This is also true for macrophages (26). Thus, professional phagocytes that encountered 
apoptotic cells become refractory to Danger signal triggering. 
A consequence of the interaction ofapoptotic bodies and phagocytic cells: induction of 
regulatory T cells 
The consequences of apoptotic cell-phagocyte interactions influence the differentiation of naïve 
CD4
+
 T cells. Although contact with apoptotic cells blocks the ability of maturation and cytokine 
production of conventional dendritic cells, their migration capabilities are not affected or at least 
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redefined. So, dendritic cells can acquire the expression of CCR7 and migrate in response to 
gradients of CCL19 and CCL21 to the lymph nodes closest to the site where the cells died (37, 
38). In the lymph nodes, such dendritic cells can interact with naive CD4
+
 T cells and deliver a 
"tolerogenic” signal to the T cellfavoring T cell commitment to a regulatory phenotype, such as 
induced Foxp3
+
 regulatory T cells (Treg) or IL-10
+
 Tr1 cells (23, 39-41). Whether natural Treg 
commitment in the thymus also respects such mechanism is still uncertain. However, several 
dendritic cell subsets are able to migrate from the periphery to the thymus to transport peripheral 
antigens(42). This may occur via the capture of auto-antigens from apoptotic cells. A main 
feature of Treg generated by dendritic cells is their ability to increase production of IL-10 (43, 
44). It was also suggested that plasmacytoid dendritic cells are the dendritic cell subtype favoring 
Tr1 commitment(45). In addition, plasmacytoid dendritic cells can also promote the 
differentiation of inducible Foxp3
+
Treg(46-48).Immature plasmacytoid dendritic cells transport 
antigens from the periphery to the thymusvia the expression of CCR9, α4-integrin and functional 
binding sites for P-selectin(49), and human thymicplasmacytoid dendritic cells favor natural 
Treg generation(50, 51). 
Apoptotic cells are endowed with immunomodulatory properties by targeting innate and adaptive 
immunity at different levels like at the microenvironment level, the polarization of antigen 
presenting cells,T and B cells. Generation of regulatory B cells (Breg) has also been 
reported(52). The immunomodulatory microenvironment created through apoptotic cell 
elimination suggests that apoptotic cell injection might be a powerful tool to control 
inflammation and restore tolerance in vivo. Thus, our group and others have demonstrated in 
various experimental models that indeed apoptotic cell injection can control inflammation 
allowing the restoration of homeostasis and in some settings, tolerance induction (Table 1). 
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These accumulated data also favored the initiation of clinical trials, the first one demonstrating 
the safety of the approach and the second one the efficacy of the approach. 
CONCLUSION:TRANSLATIONTO ANTI-NEUTROPHIL CYTOPLASMIC AUTO-ANTIBODY(ANCA)-
ASSOCIATED VASCULITIS 
Neutrophil apoptosis may play a role in the pathogenesis of anti-neutrophil cytoplasmic auto-
antibody (ANCA)-associated systemic vasculitis(53). Several tracks have been proposed to 
explain its role in the pathophysiological process of ANCA-associated vasculitis. Apoptotic 
neutrophils can be considered as a Danger signal since they contain a lot of proteases, including 
serine proteases and elastase(54). However, repeated infusion of apoptotic neutrophils in brown 
Norway rats has been shown to induce ANCA, but did not lead to systemic vasculitis(55). This 
suggests that apoptotic neutrophils by themselves are not sufficient to trigger the complete 
clinical features of ANCA-associated vasculitis. Recent works by Witko-Sarsat and colleagues 
(56, 57)suggest that proteinase-3, the target of ANCA in granulomatosis with polyangiitis, delays 
apoptotic neutrophil removal when expresses at the cell membrane and leads to enhanced 
secretion of pro-inflammatory cytokines, including: TNF, IL-8 and MIP-1β.So, restoring 
efficient apoptotic neutrophil uptake can be considered as a potential therapeutic approach to 
treat ANCA-associated vasculitis. 
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Table 1.Therapeutic applications of apoptotic cell administration 
 References 
Chronic inflammatory autoimmune 
diseases 
 
Diabetes Xia, 2007 (41); Mougel, 2012 (58) 
Experimental Autoimmune 
Encephalomyelitis 
Miyake, 2007 (28); Qiu, 2009 (59) 
Arthritis Gray, 2007 (52); Perruche, 2009 (26); 
Notley, 2011 (60) 
Acute inflammatory diseases  
Sepsis Huynh, 2002 (61); Ren, 2008 (62) 
Fulminant hepatitis Zhang, 2011 (63) 
Contact hypersensitivity Griffith, 2007 (64) 
Transplantation  
Cardiac allograft  
Acute rejection Sun, 2004 (65); Wang, 2006 (66) 
Chronic rejection Wang, 2009 (67) 
Islets allograft Mougel, 2012(68) 
Hematopoietic cell transplantation  
Hematopoietic engraftment Bittencourt, 2001 (69); Kleinclauss, 2006 
(39); Perruche, 2004 (70); Bonnefoy, 2011 
(48) 
Graft-versus-host disease Kleinclauss, 2006 (39) 
Allo-antibodies after graft rejection Perruche, 2004 (70) 
Acute myocardial infarction Ankersmith, 2009 (71); Lichtenauer, 2011 
(72) 
Adapted from (73) 
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Figure 1.Different signals involved in apoptotic cell removal. Different signals orchestrate 
apoptotic cell removal by neighbor cells or professional phagocytes such as macrophages. This 
includes: 1) the loss of “don’t eat me” signals; 2) the secretion of “find me” signals that can be 
counterbalanced by “keep out” signals(74, 75); 3) the acquisition of “eat me”signals.Adapted 
from Ref.and updated with the following reviews(8, 9) and original publications(76, 77). 
Abbreviations used:BAI-1, Brain Angiogenesis Inhibitor-1; CRP, C reactive protein; CRT, 
calreticulin; Gas6, Growth Arrest 6; MBP, Mannose Binding Protein; MFG-E8, lactadherin; PS, 
phosphatidylserines; PSR, phosphatidylserine receptors; PR3, proteinase-3; RAGE, receptor for 
advanced glycation end products; SRA, Scavenger Receptor A; TSP1, thrombospondin-1. 
